Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Michèle Mathieu.
Nature Genetics | 2006
Yanick J. Crow; Andrea Leitch; Bruce E. Hayward; Anna Garner; Rekha Parmar; Elen Griffith; Manir Ali; Colin A. Semple; Jean Aicardi; Riyana Babul-Hirji; Clarisse Baumann; Peter Baxter; Enrico Bertini; Kate Chandler; David Chitayat; Daniel Cau; Catherine Déry; Elisa Fazzi; Cyril Goizet; Mary D. King; Joerg Klepper; Didier Lacombe; Giovanni Lanzi; Hermione Lyall; María Luisa Martínez-Frías; Michèle Mathieu; Carole McKeown; Anne Monier; Yvette Oade; Oliver Quarrell
Aicardi-Goutières syndrome (AGS) is an autosomal recessive neurological disorder, the clinical and immunological features of which parallel those of congenital viral infection. Here we define the composition of the human ribonuclease H2 enzyme complex and show that AGS can result from mutations in the genes encoding any one of its three subunits. Our findings demonstrate a role for ribonuclease H in human neurological disease and suggest an unanticipated relationship between ribonuclease H2 and the antiviral immune response that warrants further investigation.
Journal of Medical Genetics | 2010
M. Willems; D Geneviève; G Borck; Clarisse Baumann; G. Baujat; Eric Bieth; C Farra; Marion Gerard; Delphine Héron; Bruno Leheup; M. Le Merrer; Stanislas Lyonnet; Dominique Martin-Coignard; Michèle Mathieu; Christel Thauvin-Robinet; A Verloes; Laurence Colleaux; Arnold Munnich; Valérie Cormier-Daire
Microcephalic osteodysplastic primordial dwarfism type II (MOPD II, MIM 210720) and Seckel syndrome (SCKL, MIM 210600) belong to the primordial dwarfism group characterised by intrauterine growth retardation, severe proportionate short stature, and pronounced microcephaly. MOPD II is distinct from SCKL by more severe growth retardation, radiological abnormalities, and absent or mild mental retardation. Seckel syndrome is associated with defective ATR dependent DNA damage signalling. In 2008, loss-of-function mutations in the pericentrin gene (PCNT) have been identified in 28 patients, including 3 SCKL and 25 MOPDII cases. This gene encodes a centrosomal protein which plays a key role in the organisation of mitotic spindles. The aim of this study was to analyse PCNT in a large series of SCKL-MOPD II cases to further define the clinical spectrum associated with PCNT mutations. Among 18 consanguineous families (13 SCKL and 5 MOPDII) and 6 isolated cases (3 SCKL and 3 MOPD II), 13 distinct mutations were identified in 5/16 SCKL and 8/8 MOPDII including five stop mutations, five frameshift mutations, two splice site mutations, and one apparent missense mutation affecting the last base of exon 19. Moreover, we demonstrated that this latter mutation leads to an abnormal splicing with a predicted premature termination of translation. The clinical analysis of the 5 SCKL cases with PCNT mutations showed that they all presented minor skeletal changes and clinical features compatible with MOPDII diagnosis. It is therefore concluded that, despite variable severity, MOPDII is a genetically homogeneous condition due to loss-of-function of pericentrin.
Journal of Medical Genetics | 2010
Céline Bonnet; Joris Andrieux; Mylène Béri-Dexheimer; Bruno Leheup; Odile Boute; S Manouvrier; Bruno Delobel; Henri Copin; Aline Receveur; Michèle Mathieu; G Thiriez; C Le Caignec; A David; Mc De Blois; Valérie Malan; Anne Philippe; Valérie Cormier-Daire; Laurence Colleaux; Elisabeth Flori; H Dollfus; V Pelletier; Christel Thauvin-Robinet; Alice Masurel-Paulet; L. Faivre; Marc Tardieu; Nadia Bahi-Buisson; Patrick Callier; Francine Mugneret; Philippe Jonveaux; D. Sanlaville
Background Genome-wide screening of large patient cohorts with mental retardation using microarray-based comparative genomic hybridisation (array-CGH) has recently led to identification several novel microdeletion and microduplication syndromes. Methods Owing to the national array-CGH network funded by the French Ministry of Health, shared information about patients with rare disease helped to define critical intervals and evaluate their gene content, and finally determine the phenotypic consequences of genomic array findings. Results In this study, nine unrelated patients with overlapping de novo interstitial microdeletions involving 4q21 are reported. Several major features are common to all patients, including neonatal muscular hypotonia, severe psychomotor retardation, marked progressive growth restriction, distinctive facial features and absent or severely delayed speech. The boundaries and the sizes of the nine deletions are different, but an overlapping region of 1.37u2005Mb is defined; this region contains five RefSeq genes: PRKG2, RASGEF1B, HNRNPD, HNRPDL and ENOPH1. Discussion Adding new individuals with similar clinical features and 4q21 deletion allowed us to reduce the critical genomic region encompassing two genes, PRKG2 and RASGEF1B. PRKG2 encodes cGMP-dependent protein kinase type II, which is expressed in brain and in cartilage. Information from genetically modified animal models is pertinent to the clinical phenotype. RASGEF1B is a guanine nucleotide exchange factor for Ras family proteins, and several members have been reported as key regulators of actin and microtubule dynamics during both dendrite and spine structural plasticity. Conclusion Clinical and molecular delineation of 4q21 deletion supports a novel microdeletion syndrome and suggests a major contribution of PRKG2 and RASGEF1B haploinsufficiency to the core phenotype.
Prenatal Diagnosis | 2008
Brigitte Simon-Bouy; Agnès Taillandier; Delphine Fauvert; Isabelle Brun-Heath; Jean-Louis Serre; Carmen G. Armengod; Martin G. Bialer; Michèle Mathieu; Jacques Cousin; David Chitayat; Jan Liebelt; Barbara Feldman; Marion Gérard‐Blanluet; Stefani Körtge-Jung; Cath King; Hannele Laivuori; Martine Le Merrer; Sarju Mehta; Christina Jern; Saba Sharif; Fabienne Prieur; Gabriele Gillessen-Kaesbach; Andreas Zankl; Etienne Mornet
We studied hypophosphatasia (HP) mutations in 19 cases prenatally detected by ultrasonography without familial history of HP. We correlated the mutations with the reported ultrasound signs, and discussed genetic counseling with regard to the particular dominantly inherited prenatal benign form of HP.
Human Genetics | 1993
Etienne Mornet; Any Bogyo; Christiane Deluchat; Brigitte Simon-Bouy; Michèle Mathieu; François Thépot; Marie Claude Grisard; Eric LeGuern; J. Boué; A. Boué
The phenotypically normal sister of a patient affected by fragile X syndrome was referred for genetic counselling and was found to carry a mosaic karyotype 46,X,r(X)/45,X. Because the probability of the simultaneous chance occurrence of fragile X syndrome and a ring chromosome X in the same family is very low, we postulated that the breakpoint of the ring chromosome X originated in the cytogenetic break in Xq27.3 responsible for fragile X syndrome. In order to determine the relative positions of the breakpoint on the ring chromosome X and the (CGG)n unstable sequence responsible for the fragile X mutation, we used molecular markers to analyse the telomeric regions of chromosome X in this family. The results showed that the ring chromosome X was the maternal fragile X chromosome and that the telomeric deletion on the long arm encompassed the (CGG)n sequence. This suggests that the cytogenetic break in Xq27.3 is distinct from the unstable (CGG)n sequence, or that the break followed by the end-to-end fusion creating the ring chromosome was not completely conservative. Analysis of DNA markers on the short arm of chromosome X evidenced a deletion of a large part of the pseudoautosomal region, allowing us to position the genes involved in stature and in some syndromes associated with telomeric deletions of Xp on the proximal side of the pseudoautosomal region.
PLOS Genetics | 2005
Catherine Dodé; Luis Teixeira; Jacqueline Levilliers; Corinne Fouveaut; Philippe Bouchard; Marie-Laure Kottler; James Lespinasse; Anne Lienhardt-Roussie; Michèle Mathieu; Alexandre Moerman; Graeme Morgan; Arnaud Murat; Jean-Edmont Toublanc; Slawomir Wolczynski; Marc Delpech; Christine Petit; Jacques Young; Jean-Pierre Hardelin
Human Molecular Genetics | 1997
Sonia Abdelhak; Vasiliki Kalatzis; Roland Heilig; Sylvie Compain; Delphine Samson; Christophe Vincent; Fabienne Levi-Acobas; Corinne Cruaud; Martine Le Merrer; Michèle Mathieu; Rainer König; Jacqueline Vigneron; Jean Weissenbach; Christine Petit; Dominique Weil
American Journal of Human Genetics | 1993
C. Desmaze; M Prieur; F. Amblard; M. Aïkem; F. LeDeist; S. Demczuk; J. Zucman; B. Plougastel; O. Delattre; M.-F. Croquette; G.-M. Brevière; C. Huon; M. Le Merrer; Michèle Mathieu; Daniel Sidi; Jean-Louis Stephan; A. Aurias
Nature Genetics | 1994
Damien Bonnet; Anna Pelet; Laurence Legeai-Mallet; Daniel Sidi; Michèle Mathieu; Philippe Parent; Henri Plauchu; Françoise Serville; Albert Schinzel; Jean Weissenbach; J. Kachaner; Arnold Munnich; Stanislas Lyonnet
Annales De Genetique | 1997
Michèle Mathieu; C. Piussan; F. Thepot; A. Gouget; Didier Lacombe; J. M. Pedespan; Françoise Serville; D. Fontan; M. Ruffie; A. Nivelon-Chevallier; F. Amblard; P. Chauveau; H. Moirot; J. P. Chabrolle; M.-F. Croquette; M. Teyssier; H. Plauchu; M. C. Pelissier; S. Gilgenkrantz; C. Turc-Carel; Catherine Turleau; M Prieur; M. Le Merrer; Marie Gonzales; Nicole Joyé; J.-L. Taillemite; J. Bouillie; C. Eschard; J. Motte; Hubert Journel